Posted 08 February, 2021
Terns Pharmaceuticals, Inc. IPO completed
IPO completed detected for ticker Nasdaq:TERN in a 424B4 filed on 08 February, 2021.
This is an initial public offering of shares of common stock of Terns Pharmaceuticals, Inc.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Terns Pharmaceuticals, Inc.
Health Care/Life Sciences • Biotechnology
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.Market Cap
$501M
View Company Details
$501M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.